Sign in
Not yet taking people in NetherlandsPhase 2

Tests tamoxifen with ruxolitinib in people with myelofibrosis

Tests tamoxifen added to ruxolitinib in adults with myelofibrosis, a blood disease.

Key facts

Who runs it
Universitair Medisch Centrum Groningen
Where
Groningen, NetherlandsSee the site
Registry title
RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis
Status
Not yet recruiting
Phase
Phase 2
People taking part
14 people, planned
Started
1 Nov 2025
Expected to end
1 Mar 2027
Type of study
Interventional
Record updated
11 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with myelofibrosis. It tests tamoxifen together with ruxolitinib.

Age
18 years or older
Sex
All sexes can join

Where in Netherlands

  • Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests tamoxifen with ruxolitinib in people with myelofibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 November 2025